形式
powder
质量水平
药品控制
USDEA Schedule IV; Home Office Schedule 3; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)
创始人
Bayer
SMILES字符串
CCC1(C(=O)NC(=O)NC1=O)c2ccccc2
InChI
1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
InChI key
DDBREPKUVSBGFI-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
Anesthetic; sedative; hypnotic; anticonvulsant
特点和优势
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语:
Danger
危险分类
Acute Tox. 3 Oral - Carc. 2 - Repr. 1B - Skin Sens. 1
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
法规信息
监管及禁止进口产品
Molecules (Basel, Switzerland), 27(9) (2022-05-15)
Hepatocellular carcinoma (HCC) is a common type of liver cancer and is a leading cause of death worldwide. Signal transducer and activator of transcription 3 (STAT3) is involved in HCC progression, migration, and suppression of apoptosis. This study investigates the
Experimental neurology, 349, 113954-113954 (2021-12-20)
The discovery and development of novel antiseizure drugs (ASDs) that are effective in controlling pharmacoresistant spontaneous recurrent seizures (SRSs) continues to represent a significant unmet clinical need. The Epilepsy Therapy Screening Program (ETSP) has undertaken efforts to address this need
Epilepsia, 53 Suppl 8, 40-46 (2012-12-12)
This article reviews the current position of phenobarbital using articles published since 2000 and speculates on its likely future contribution to epilepsy care. Over the last decade there have been no major double-blind randomized placebo-controlled or comparative trials with phenobarbital.
Acta paediatrica (Oslo, Norway : 1992), 102(9), 863-867 (2013-06-07)
Treatment of neonatal seizures still relies primarily on phenobarbital, despite an estimated efficacy of less than 50% and concern over neurodegenerative side effects. The objective of this study was to evaluate the efficacy and safety of lidocaine as second-line treatment
Expert opinion on investigational drugs, 22(3), 299-307 (2013-02-12)
This prospective study aimed at investigating the efficacy and safety of the concurrent use of celecoxib (CXB) with 5-fluorouracil, epirubicin and cyclophosphamide (FEC), followed by docetaxel (T) in the neoadjuvant setting. A total of 64 invasive breast cancer patients were
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门